Skip to content

Epidemiology and burden

TL;DR — Dementia burden is growing almost entirely through demography rather than through rising age-specific risk: GBD 2019 projected 57.4 million cases (95% UI 50.4–65.1) in 2019 rising to 152.8 million (130.8–175.9) by 2050 while age-standardised prevalence stayed flat (global change 0.1%, −7.5 to 10.8), with the largest relative increases in north Africa and the Middle East (367%) and eastern sub-Saharan Africa (357%) (GBD 2019 Dementia Forecasting Collaborators 2022, PMID 34998485). Age-specific incidence has fallen in Western high-income cohorts — 13% per calendar decade across seven European and US cohorts over 27 years (95% CI 7–19%) — while Japan's Hisayama cohort rose until about 2012 and then fell, so "the risk is declining" is a statement about particular populations and eras, not a global law (Wolters 2020, PMID 32611641; Ohara 2025, PMID 41466306). In the US, nationally representative neuropsychological testing put dementia prevalence at 10% (95% CI 9–11) and MCI at 22% (20–24) among adults 65+ in 2016, and lifetime risk after age 55 in the ARIC cohort was 42% (95% CI 41–43) (Manly 2022, PMID 36279130; Fang 2025, PMID 39806070). Global societal cost was estimated at US$1,313.4 billion in 2019, about half of it unpaid care, with 61% of people with dementia living in low- and middle-income countries but 74% of the costs occurring in high-income countries (Wimo 2023, PMID 36617519). The largest measurement problem is ascertainment: in STRiDE community surveys fewer than 1% of people meeting dementia criteria in Indonesia and South Africa had ever been diagnosed, so the epidemiological numbers and the health-system numbers describe different populations (Farina 2023, PMID 37278200).

What is being counted

Most population statistics count dementia, not Alzheimer's disease. Only autopsy and biomarker studies count Alzheimer's neuropathologic change directly, and the biological definition makes the gap explicit: a person can carry Alzheimer pathology without dementia and can have dementia driven by other or additional pathologies. Community autopsy data show that in people with dementia the commonest configuration was Alzheimer pathology plus infarcts (38.0%), exceeding pure Alzheimer pathology (30.0%), and over half had more than one diagnosis (Schneider 2007, PMID 17568013). Whenever a source says "Alzheimer's disease and other dementias", the category is a syndromic aggregate; see mixed pathology and vascular contribution.

Counting frame What it measures Typical source Principal bias
Clinical diagnosis in records/claims Health-system recognition Medicare, HES, registries Under-ascertainment, differential by race, education and setting (PMID 34091580)
Population survey with cognitive testing Syndromic dementia by algorithm HRS-HCAP, LASI-DAD, 10/66 Instrument and threshold dependence (PMID 36279130; PMID 38324518)
Modelled global estimates Prevalence, deaths, DALYs GBD Sparse input data in many countries; death-coding correction (PMID 30497964)
Death certification Deaths attributed to dementia Vital registration Coding practice changes over time more than biology does (PMID 38689398)
Autopsy cohorts Neuropathologic change Community brain banks Selection into brain donation; small n (PMID 17568013)

Global prevalence, incidence and forecasts

Metric Estimate (95% UI) Year Source
People living with dementia 57.4 million (50.4–65.1) 2019 GBD 2019 forecast (PMID 34998485)
Projected people living with dementia 152.8 million (130.8–175.9) 2050 GBD 2019 forecast (PMID 34998485)
Change in age-standardised prevalence 2019→2050 +0.1% (−7.5 to 10.8) — GBD 2019 forecast (PMID 34998485)
Female-to-male prevalence ratio 1.69 (1.64–1.73) 2019 GBD 2019 forecast (PMID 34998485)
People living with dementia 43.8 million (37.8–51.0) 2016 GBD 2016 dementia (PMID 30497964)
Increase in count 1990→2016 +117% (114–121) — GBD 2016 dementia (PMID 30497964)
Change in age-standardised prevalence 1990→2016 +1.7% (1.0–2.4) — GBD 2016 dementia (PMID 30497964)
Deaths attributed to dementia 2.4 million (2.1–2.8) 2016 GBD 2016 dementia (PMID 30497964)
Dementia DALYs 28.8 million (24.5–34.0) 2016 GBD 2016 dementia (PMID 30497964)
DALYs attributable to four modelled risks 6.4 million (3.4–10.5) 2016 GBD 2016 dementia (PMID 30497964)

The two GBD rounds are not interchangeable: 43.8 million in 2016 and 57.4 million in 2019 differ by model vintage as well as by calendar time, and the second is a forecasting analysis with education and three risk factors as predictors. The consistent structural finding across both is that the increase is driven by population growth and ageing rather than by a rising age-standardised rate; in the 2019 analysis, decomposition attributed most of the projected growth to those demographic terms, with population growth dominating in sub-Saharan Africa and ageing dominating in east Asia (PMID 34998485).

At a whole-nervous-system level, GBD 2021 ranked Alzheimer's disease and other dementias among the ten conditions with the highest age-standardised DALYs, within a group of 37 neurological conditions that together were the leading cause of DALYs globally (443 million, 95% UI 378–521) (GBD 2021 Nervous System Disorders Collaborators 2024, PMID 38493795).

Regional heterogeneity is not a rounding error

The projected 2019→2050 increases range from 53% (41–67) in high-income Asia Pacific and 74% (58–90) in western Europe to 367% (329–403) in north Africa and the Middle East and 357% (323–395) in eastern sub-Saharan Africa (PMID 34998485). Almost all of the incremental care demand therefore arises in health systems that currently have the least dementia-specific diagnostic and long-term-care capacity — the same asymmetry that appears in the cost data below and in care, caregiving and health systems.

Age structure of risk

Incidence rises steeply and does not plateau at the top of the age range. In the pooled Alzheimer Cohorts Consortium data, all-cause dementia incidence ranged from about 4 per 1,000 person-years at ages 65–69 to 65 per 1,000 person-years at ages 85–89 (Wolters 2020, PMID 32611641). The 90+ Study found an overall incidence of 18.2% per year (95% CI 15.3–21.5) above age 90, rising from 12.7% per year at 90–94 to 21.2% at 95–99 and 40.7% at 100+, with a Poisson doubling time of 5.5 years (Corrada 2010, PMID 20186856). A multiracial health-system cohort of people aged ≥90 found rates of 89.9 (Asian), 96.9 (White), 105.8 (Latino) and 121.5 (Black) per 1,000 person-years, showing that racial/ethnic differences persist into the oldest ages though attenuated (Gilsanz 2019, PMID 30797730).

Young-onset dementia is a distinct planning problem. Global age-standardised prevalence in the 30–64 range was 119.0 per 100,000, corresponding to about 3.9 million people worldwide, and global age-standardised incidence was 11 per 100,000 in ages 30–64, about 370,000 new cases annually (Hendriks 2021, PMID 34279544; Hendriks 2023, PMID 35715891). Both meta-analyses report high heterogeneity and sparse data below age 50, and the prevalence review found lower crude estimates in high-income than in middle-income countries — a pattern more plausibly explained by study methods than by biology.

Are rates falling?

Population / design Result Interpretation
7 cohorts, US + Europe, 49,202 people, 1988–2015 Incidence declined 13% per calendar decade (95% CI 7–19); 24% (14–32) in men vs 8% (0–15) in women Consistent decline across Western cohorts (Wolters 2020, PMID 32611641)
Framingham Heart Study, 5,205 people ≥60, four epochs from late 1970s 5-year cumulative hazard 3.6 → 2.8 → 2.2 → 2.0 per 100 persons (declines of 22%, 38%, 44% vs first epoch); decline only among those with ≥ high-school diploma (HR 0.77, 0.67–0.88) Longest consistent-criteria single-cohort demonstration; vascular-risk trends do not fully explain it (Satizabal 2016, PMID 26863354)
Meta-analysis of 5 high-quality high-income cohort studies Pooled incidence change 0.82 (95% CI 0.51–1.33), I²=94.9%; 0.69 (0.47–1.00) excluding Hisayama Decline is directionally consistent but not statistically robust when pooled (Roehr 2018, PMID 30271219)
Gothenburg 85-year-olds, 1986–87 vs 2008–10 Dementia prevalence 29.8% → 21.7% (OR 0.66, 95% CI 0.50–0.86), mainly vascular dementia Education and reduced stroke-associated risk explained most of the fall (Skoog 2017, PMID 28733627)
Hisayama, Japan, 1985–2012 Age-standardised all-cause dementia prevalence 6.8% → 11.3%; AD prevalence 1.5% → 7.2%; VaD flat; incidence aHR 1.68 (1.38–2.06) 1988→2002 cohort Rising AD incidence plus improved survival (Ohara 2017, PMID 28424272)
Hisayama, extended to 2022 Crude prevalence 17.9% (2012) → 15.8% (2017) → 12.1% (2022); incidence aHR 0.60 (0.51–0.70) from 2002 to 2012 cohort The Japanese exception reversed after 2012 (Ohara 2025, PMID 41466306)

Three inferences follow. First, an age-standardised decline in one era does not license extrapolation: the same cohort produced a rise and then a fall within four decades. Second, survival change confounds prevalence trends — Hisayama's 5-year survival after dementia onset improved from 47.3% to 65.2% between the 1988 and 2002 cohorts, which by itself raises prevalence (PMID 28424272). Third, the decline that has been observed is concentrated in vascular contributions and in cohorts with rising education, which is the empirical bridge to risk reduction and prevention.

National and regional estimates

Population Estimate Method Source
US adults 65+, 2016 Dementia 10% (95% CI 9–11); MCI 22% (20–24) HRS-HCAP neuropsychological battery + informant, n=3,496 Manly 2022, PMID 36279130
US adults 65+, 2014 5.0 million with ADRD (1.6% of population) Medicare fee-for-service prevalence applied to census Matthews 2019, PMID 30243772
US adults 65+, 2060 projection 13.9 million (3.3% of population) Same model, census projections Matthews 2019, PMID 30243772
US adults 65+, 2024 6.9 million with Alzheimer's dementia; 13.8 million by 2060 Alzheimer's Association compiled estimates 2024 Facts and Figures, PMID 38689398
US, lifetime risk from age 55 42% (95% CI 41–43); ~45–60% in women, Black adults, APOE ε4 carriers ARIC, n=15,043, death as competing risk Fang 2025, PMID 39806070
US annual incident cases ~514,000 (2020) → ~1,000,000 (2060) Lifetime-risk estimates applied to census projections Fang 2025, PMID 39806070
India, 60+ Major neurocognitive disorder 7.2%; mild 17.6% LASI-DAD, DSM-5 algorithm, n=4,096, nationally representative Gross 2024, PMID 38324518
Indonesia, 65+ 27.9% (95% CI 25.2–28.9) STRiDE, 10/66 short schedule, n=2,110 Farina 2023, PMID 37278200
South Africa, 65+ 12.5% (95% CI 9.5–16.0) STRiDE, 10/66 short schedule, n=408 Farina 2023, PMID 37278200

The Indonesian figure is far above what the GBD age-standardised model implies for the region, and the two estimates are kept side by side rather than reconciled: the 10/66 algorithm and a modelled synthesis are different instruments, and STRiDE's South African sample was small (n=408). What both STRiDE sites agree on is the diagnosis gap — 0.2% of Indonesian and 0.5% of South African participants had a previous dementia diagnosis (PMID 37278200).

Sex, race, ethnicity and diagnosis gaps

More women than men live with dementia in every global estimate (27.0 million vs 16.8 million in 2016; female-to-male prevalence ratio 1.69 in 2019) (PMID 30497964; PMID 34998485). Whether this reflects longer survival, differential risk, or diagnostic artefact is not settled by prevalence data: the ACC incidence analysis found similar incidence rates in men and women, with declines somewhat larger in men (24% vs 8% per decade), and HRS-HCAP found no prevalence difference by sex after accounting for the sampled age structure (PMID 32611641; PMID 36279130).

Racial and ethnic differences in the US are large and reproducible across designs. In 274,283 health-plan members aged 64+, 14-year incidence ranged from 15.2 per 1,000 person-years in Asian Americans to 26.6 in African Americans, a 65% higher hazard for African Americans versus Asian Americans (HR 1.65, 95% CI 1.58–1.72), with 25-year cumulative risk from age 65 of 38% versus 28% (Mayeda 2016, PMID 26874595). HRS-HCAP found dementia more common in non-Hispanic Black participants (OR 1.81, 95% CI 1.20–2.75) and MCI more common in Hispanic participants (OR 1.42, 1.03–1.96), and each additional year of education was associated with lower odds of dementia (OR 0.93, 0.89–0.97) (PMID 36279130).

Recognition is unequally delayed. Among 3,966 HRS participants aged 70+ with probable dementia linked to claims, a missed or delayed clinical diagnosis occurred in 41% of non-Hispanic White, 46% of non-Hispanic Black and 54% of Hispanic participants, with mean estimated delays of 31.2, 34.6 and 43.8 months respectively (Lin 2021, PMID 34091580). Because eligibility for anti-amyloid immunotherapy is restricted to early-stage disease, a delay measured in years is not only an equity problem but a treatment-access mechanism.

Mortality and survival

Dementia is under-recorded as a cause of death and over-interpreted when it is recorded. US death certificates recorded 119,399 Alzheimer's deaths in 2021, and reported AD deaths rose more than 140% between 2000 and 2021 while stroke, heart disease and HIV deaths fell — a divergence that reflects certification practice and population ageing as much as incidence (2024 Facts and Figures, PMID 38689398). GBD explicitly models dementia mortality from prevalence and excess mortality because of exactly this coding instability (PMID 30497964).

Outcome Estimate Population Source
All-cause mortality, any dementia vs no dementia HR 5.90 (95% CI 3.53–9.86) 78 studies, 63,125 with dementia vs 152,353 controls Liang 2021, PMID 36097997
Mean survival from AD diagnosis 5.8 years (SD 2.0) Same synthesis PMID 36097997
Non-AD dementia vs AD, mortality HR 1.33 (1.21–1.46) Same synthesis PMID 36097997
Survival from diagnosis, non-AD vs AD −1.12 years (−1.52 to −0.72) Same synthesis PMID 36097997
Highest mortality subtype Lewy body dementia, HR 17.88 (5.87–54.46) Same synthesis PMID 36097997
5-year survival after dementia onset 47.3% (1988 cohort) → 65.2% (2002) → 58.9% (2012, ns) Hisayama, Japan Ohara 2025, PMID 41466306

Heterogeneity was large (I²>75% for most outcomes) and half of the included studies were rated good quality, so the pooled hazard ratios describe direction and rough magnitude rather than a transportable number (PMID 36097997).

Health-system and care burden

Emergency hospital use is the point where dementia becomes visible to acute services. Across 5,580,106 emergency admissions in England, people with dementia accounted for 13.9% of male and 18.6% of female admissions aged 65+; after covariate adjustment, length of stay was 17% (95% CI 15–18) longer for men and 12% (10–14) longer for women with dementia, adjusted excess emergency re-admission risk was 17%, and — the largest signal — the risk of dying within 30 days of discharge was roughly doubled (Reeves 2023, PMID 36888666). Institutional transition is driven by cognition, behavioural and psychological symptoms, and function rather than by the diagnosis alone: a meta-analysis of 26 controlled studies found poorer cognition, neuropsychiatric symptoms and ADL impairment consistently associated with nursing-home admission, with caregiver burden an additional determinant (Toot 2017, PMID 27806743).

Cost measure Estimate Year Source
Global societal cost of dementia US$1,313.4 billion (US$23,796 per person with dementia) 2019 Wimo 2023, PMID 36617519
— direct medical US$213.2 billion (16%) 2019 PMID 36617519
— direct social sector incl. long-term care US$448.7 billion (34%) 2019 PMID 36617519
— informal care US$651.4 billion (50%) 2019 PMID 36617519
Share of people with dementia in LMICs vs share of costs in HICs 61% vs 74% 2019 PMID 36617519
Direct health-care spending attributable to ADRD (204 countries) US$260.6 billion (95% UI 131.6–420.4) 2019 Lastuka 2024, PMID 39150827
Informal care cost (same model) US$354.1 billion (95% UI 190.0–544.1); 57% of total 2019 PMID 39150827
Projected direct spending US$1.6 trillion (0.6–3.3), 9.4% of world health spending 2050 PMID 39150827
US unpaid caregivers / hours >11 million people, 18.4 billion hours 2023 PMID 38689398
Valuation of US unpaid care US$346.6 billion 2023 PMID 38689398
US payments for health, long-term and hospice care, 65+ with dementia US$360 billion 2024 PMID 38689398

Wimo's US$1,313.4 billion and Lastuka's US$614.7 billion (direct plus informal) are not averaged here: they use different cost bases, different informal-care valuation methods and different imputation for countries without data. The stable finding across both is that informal care is roughly half the total, meaning the majority of the economic burden of dementia is not recorded in any health budget — the substrate for caregiving and health systems.

Two quantities that should not be averaged away

Secular decline is not demographically uniform. In northern Manhattan, the cohort recruited in 1999 had 41% lower dementia incidence than the 1992 cohort after adjustment (HR 0.59); stratum estimates were 0.60 for non-Hispanic White, 0.52 for African-American and 0.64 for Hispanic participants, with the reduction associated with higher educational attainment (Noble 2017, PMID 28984588). This supports a preventability signal while warning against exporting the magnitude across populations.

AD-specific cost-of-illness studies are both sparse and heterogeneous: only 12 of 5,536 screened studies met criteria in a 2024 review, and annual per-person estimates ranged from US$468.28 for mild AD to US$171,283.80 for severe AD. Informal caregiving dominated community costs, whereas formal accommodation shifted as much as 67.3% of the total into direct cost (Tay 2024, PMID 37972428). A broader dementia review found an average annual estimate of US$30,554 across 27 studies and 14 health systems, with informal care and nursing homes as the main drivers (Schaller 2015, PMID 25320002). These figures measure different severity mixes, cost categories, years and systems; a pooled headline would be misleading.

Where the numbers are weakest

  • Low-income countries. GBD's largest projected increases are in the regions with the sparsest primary data; the 10/66 and STRiDE programmes exist precisely because the input data for those regions were survey-scarce (PMID 37278200).
  • Aetiological subtype. Almost no population-scale estimate separates Alzheimer's disease from other dementias by biomarker or autopsy. Hisayama is unusual in reporting AD and VaD trends separately, and it found them moving differently — AD prevalence rose 1.5%→7.2% while VaD stayed flat (PMID 28424272).
  • Ages below 50 and above 95. Young-onset meta-analyses report very sparse data below 50 (PMID 34279544); the 90+ Study is one of few sources above 95 (PMID 20186856).
  • Diagnosis-based denominators. Claims and registry counts measure recognition; when recognition changes (new blood tests, new treatments), apparent incidence changes without any change in disease.

Open questions

  • Why did incidence decline in Western cohorts while Hisayama rose to 2012 and then fell, and how much of each pattern is vascular-risk management versus education versus survival change (Wolters 2020, PMID 32611641; Ohara 2025, PMID 41466306; Skoog 2017, PMID 28733627)?
  • What is the true prevalence in sub-Saharan Africa and south Asia measured with a single harmonised instrument? The Indonesian STRiDE estimate of 27.9% and India's LASI-DAD estimate of 7.2% major neurocognitive disorder cannot both describe the same construct (PMID 37278200; PMID 38324518).
  • How much of the Black–White and Hispanic–White difference in US dementia incidence is risk and how much is measurement, given that the same groups have longer diagnostic delays and different educational quality (Mayeda 2016, PMID 26874595; Lin 2021, PMID 34091580)?
  • Does the female excess in prevalence survive incidence-based, mortality-adjusted analysis in low- and middle-income settings, where the female survival advantage differs (PMID 34998485; PMID 32611641)?
  • What happens to measured incidence when plasma biomarker testing enters primary care — is a change in ascertainment separable from a change in disease (PMID 37278200)?
  • What fraction of the projected 2050 burden is avoidable in the regions with the largest projected increases, where prevention trials have almost never been run (PMID 34998485)?

References

  1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050. Lancet Public Health. 2022;7:e105-e125. PMID 34998485.
  2. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016. Lancet Neurol. 2019;18:88-106. PMID 30497964.
  3. GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021. Lancet Neurol. 2024;23:344-381. PMID 38493795.
  4. Manly JJ, et al. Estimating the prevalence of dementia and mild cognitive impairment in the US: the 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project. JAMA Neurol. 2022;79:1242-1249. PMID 36279130.
  5. Fang M, et al. Lifetime risk and projected burden of dementia. Nat Med. 2025;31:772-776. PMID 39806070.
  6. Wolters FJ, et al. Twenty-seven-year time trends in dementia incidence in Europe and the United States: the Alzheimer Cohorts Consortium. Neurology. 2020;95:e519-e531. PMID 32611641.
  7. Roehr S, et al. Is dementia incidence declining in high-income countries? A systematic review and meta-analysis. Clin Epidemiol. 2018;10:1233-1247. PMID 30271219.
  8. Skoog I, et al. Decreasing prevalence of dementia in 85-year olds examined 22 years apart. Sci Rep. 2017;7:6136. PMID 28733627.
  9. Ohara T, et al. Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology. 2017;88:1925-1932. PMID 28424272.
  10. Ohara T, et al. Thirty-seven-year trends in the prevalence, incidence, and prognosis of dementia in a Japanese community: the Hisayama study. Alzheimers Res Ther. 2025;17:264. PMID 41466306.
  11. Corrada MM, et al. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 2010;67:114-121. PMID 20186856.
  12. Gilsanz P, et al. Incidence of dementia after age 90 in a multiracial cohort. Alzheimers Dement. 2019;15:497-505. PMID 30797730.
  13. Hendriks S, et al. Global prevalence of young-onset dementia: a systematic review and meta-analysis. JAMA Neurol. 2021;78:1080-1090. PMID 34279544.
  14. Hendriks S, et al. Global incidence of young-onset dementia: a systematic review and meta-analysis. Alzheimers Dement. 2023;19:831-843. PMID 35715891.
  15. Matthews KA, et al. Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged ≥65 years. Alzheimers Dement. 2019;15:17-24. PMID 30243772.
  16. Alzheimer's Association. 2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024;20:3708-3821. PMID 38689398.
  17. Gross AL, et al. Prevalence of DSM-5 mild and major neurocognitive disorder in India: results from the LASI-DAD. PLoS One. 2024;19:e0297220. PMID 38324518.
  18. Farina N, et al. Comprehensive measurement of the prevalence of dementia in low- and middle-income countries: STRiDE methodology and its application in Indonesia and South Africa. BJPsych Open. 2023;9:e102. PMID 37278200.
  19. Mayeda ER, et al. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement. 2016;12:216-224. PMID 26874595.
  20. Lin PJ, et al. Dementia diagnosis disparities by race and ethnicity. Med Care. 2021;59:679-686. PMID 34091580.
  21. Liang CS, et al. Mortality rates in Alzheimer's disease and non-Alzheimer's dementias: a systematic review and meta-analysis. Lancet Healthy Longev. 2021;2:e479-e488. PMID 36097997.
  22. Reeves D, et al. Retrospective study of more than 5 million emergency admissions to hospitals in England: epidemiology and outcomes for people with dementia. PLoS One. 2023;18:e0281158. PMID 36888666.
  23. Toot S, et al. Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis. Int Psychogeriatr. 2017;29:195-208. PMID 27806743.
  24. Wimo A, et al. The worldwide costs of dementia in 2019. Alzheimers Dement. 2023;19:2865-2873. PMID 36617519.
  25. Lastuka A, et al. Societal costs of dementia: 204 countries, 2000-2019. J Alzheimers Dis. 2024;101:277-292. PMID 39150827.
  26. Schneider JA, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197-2204. PMID 17568013.
  27. Satizabal CL, et al. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med. 2016;374:523-32. PMID 26863354.
  28. Noble JM, et al. Secular trends in the incidence of dementia in a multi-ethnic community. J Alzheimers Dis. 2017;60:1065-1075. PMID 28984588.
  29. Tay LX, et al. Economic burden of Alzheimer's disease: a systematic review. Value Health Reg Issues. 2024;40:1-12. PMID 37972428.
  30. Schaller S, et al. The main cost drivers in dementia: a systematic review. Int J Geriatr Psychiatry. 2015;30:111-29. PMID 25320002.